Health-care companies rose as a flight from high-risk market areas such as biotechnology slowed.
The iShares Nasdaq Biotechnology exchange-traded fund, a basket of biotech firms, ticked up roughly 1%, but remains in the red for the year to date.
British drugmaker AstraZeneca said it received European Union approval for its Imfinzi drug as a treatment for early-stage gastric and gastroesophageal cancers.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
March 16, 2026 16:59 ET (20:59 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.